相关临床试验
117
19 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1209
进行中（未招募）
11
9.4%
已完成
58
49.6%
Enrolling By Invitation
1
0.8%
尚未招募
7
6.0%
招募中
20
17.1%
Unknown
20
17.1%
暂无批准数据
- DNA sequencing of normal esophageal tissue from cancer patients shows chemotherapy and radiotherapy alter which mutant cell clones expand in healthy tissue. - Patients who received chemoradiotherapy (CROSS) had double the proportion of tissue carrying TP53 and PPM1D mutations compared with other treatment groups. - Combination chemotherapy increased normal cells carrying mutations linked to resistance to 5-fluorouracil, potentially protecting healthy tissue from toxicity. - Researchers found no chemotherapy-specific mutational signatures, suggesting most detected mutant clones pre-existed therapy and were selected rather than newly generated.
- A new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics has been established, led by the University of Cambridge with partners across the UK, Europe, and Australia. - The centre aims to define how mitochondrial DNA mutations cause disease and translate that knowledge into new therapeutic approaches for conditions affecting around 1 in 5,000 people. - The University of Manchester team will develop next-generation base editing tools to selectively target the most common disease-causing mtDNA mutations. - Currently no cure exists for mitochondrial diseases, which can cause severe disability, progressive decline, and premature death.
- GIPR agonists suppress appetite by directly stimulating receptors in the brainstem area postrema, while GIPR antagonists promote weight loss by blocking receptors in the hypothalamus. - Blocking GIPR in the hypothalamus removes an inhibitory "brake" that normally limits the brainstem's sensitivity to satiety signals, enhancing GLP-1 drug efficacy. - GIPR antagonism also sensitizes the brain to amylin receptor agonists like cagrilintide, opening new avenues for combination obesity therapeutics. - The findings provide a mechanistic blueprint explaining the clinical success of dual-action therapies like tirzepatide (Mounjaro/Zepbound) and MariTide.
- Cambridge researchers found that isosteviol combined with the antidepressant duloxetine sharply suppressed Roseburia intestinalis and Parabacteroides merdae, two bacteria linked to digestive health and blood sugar regulation. - The study tested 39 sweeteners against 25 gut bacterial species and identified over 100 interactions where sweetener effects changed when combined with other common substances like caffeine, vanillin, or medications. - In a synthetic gut community, the isosteviol-duloxetine combination reduced microbial diversity and increased toxicity toward certain host cells involved in inflammation and immune responses. - The experiments were conducted in laboratory conditions, and the researchers emphasize that human studies are needed before concluding any direct health effects in people.
- A comprehensive analysis of roughly 215,000 NHS specialty training applications from 2021–2024 found overall success rates fell from 32.7% to 17.2%. - UK-trained ethnic minority doctors and applicants who are pregnant or on maternity leave experienced considerably lower chances of appointment, with disparities widening over time. - In 2024, Black doctors were up to 30 times less likely to be offered a training post than white applicants in some specialties, such as anaesthetics CT1. - Researchers and experts call for targeted support, mentoring, and objective bias assessment to build a fair and sustainable NHS workforce.
- A nationwide genomic study of 3,514 Shigella samples found sexually transmitted strains spread an average of 117 km versus 46 km for non-sexually transmitted strains in England. - Seventy percent of sexually transmitted Shigella strains were resistant to at least one clinically relevant antibiotic, compared with 40% of non-sexually transmitted cases. - UKHSA figures show more than 2,500 cases of sexually transmitted Shigella in England in 2025, up from just over 2,000 in 2023. - Researchers stress that standard hygiene measures are ineffective against sexual transmission and call for urgent development of vaccines, clearance pathways, and tailored treatment guidelines.
- Severe pneumonia comprises three distinct biological subtypes, or "pneumotypes," that are indistinguishable by standard clinical presentation but strongly linked to patient recovery trajectories. - The most common subtype (49% of cases) features immune suppression and lung lining damage with minimal inflammation, potentially explaining why anti-inflammatory therapies fail or harm some patients. - A balanced immune response subtype (23% of cases) was associated with the fastest recovery and shortest ventilator time, despite initially comparable illness severity. - The most dangerous subtype showed persistent severe inflammation with immature immune cells, and these patients may benefit most from targeted anti-inflammatory therapies.
- A Phase 1 trial in 39 healthy volunteers demonstrated that an AI-designed universal Sarbeco coronavirus vaccine is safe with no significant side effects. - The vaccine, developed by the University of Cambridge and DIOSynVax, triggered immune responses against SARS-CoV-2, SARS, and related bat viruses with pandemic potential. - This marks the first time a vaccine whose active component was designed entirely by computer simulations has been tested in humans. - The technology uses a machine learning-designed "super-antigen" to provide broad protection across entire virus families, potentially eliminating the need for annual reformulation.
- NVision secured $55 million in Series B funding led by Abbott to expand its quantum-based cancer imaging technology and venture into quantum computing for drug development. - The company's POLARIS platform uses quantum technology to enhance MRI signals by over 10,000 times, enabling real-time metabolic imaging that can determine treatment efficacy within days rather than months. - NVision plans to deploy approximately 20 systems across major cancer centers by year-end and expects to begin human clinical studies in 2027 following regulatory discussions. - The company is developing quantum computing capabilities using organic molecule-based qubits to design new drug candidates for previously "undruggable" targets, combining computational design with rapid biological validation.
- AndzonBio2 has signed agreements with the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise to develop novel therapeutics targeting neuroinflammation in neurodegenerative diseases. - The collaboration aims to advance a first-in-class therapeutic program designed to modulate key pathways involved in neuroinflammatory processes affecting conditions like Parkinson's, Alzheimer's, and ALS. - Cambridge Enterprise grants AndzonBio2 an exclusive option to license resulting intellectual property and advance the program through preclinical and clinical development phases. - The partnership addresses a critical unmet medical need, as neurological and neurodegenerative disorders affect over 3 billion people worldwide with limited effective disease-modifying treatments available.
